Health Trials

Waldenström Macroglobulinemia

3

Review clinical trials related to Waldenström Macroglobulinemia. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)

Participants needed: 645
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: BeOne MedicinesUpdated: Jun 18, 2026Locations: 127
Eligibility criteria

Confirmed diagnosis (per World Health Organization (WHO) guidelines, unless othe... [+6]

Prior malignancy (other than the disease under study) within the past 2 years, e... [+4]

Read more
Status: Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

This study aims to explore the recommended phase 2 dose and evaluate the safety, tolerability and preliminary antitumor activity of BGB-16673 monotherapy at the recommended Phase 2 dose for the selected B-cell malignancy expansion cohorts

Participants needed: 146
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: BeiGeneUpdated: Apr 17, 2026Locations: 29
Eligibility criteria

Provision of signed and dated written informed consent prior to any study [+5]

Prior malignancy (other than the disease under study) within the past 2 years, e... [+4]

Read more
Status: Recruiting

A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenström macroglobulinemia (WM). The name of the study drug involved in this study is: -Pacritinib (a type of kinase inhibitor)

Participants needed: 30
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Shayna Sarosiek, MDUpdated: Dec 5, 2025Locations: 1
Eligibility criteria

Age ≥18 years [+20]

Current history of uncontrolled HIV [+21]

Read more